LUNG Q4 2025 Earnings Call Summary

Summary of Pulmonx (LUNG) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

Q4 2025 Revenue: $22.6 million, a 5% decrease from $23.8 million in Q4 2024.
Full Year 2025 Revenue: $90.5 million, an 8% increase year-over-year.
U.S. Revenue Q4 2025: $14.1 million, an 11% decrease from $15.9 million in Q4 2024.
International Revenue Q4 2025: $8.5 million, an 8% increase year-over-year.
Gross Margin Q4 2025: 77.6%, up from 74% in Q4 2024.
Operating Expenses Q4 2025: $27.4 million, an 11% decrease year-over-year.
Net Loss Q4 2025: $10.4 million, or $0.25 per share, improved from a loss of $13.2 million or $0.33 per share in Q4 2024.
Cash Position: $69.8 million at year-end, down $31.7 million from the previous year.

2. Strategic Updates and Business Highlights

Leadership Changes: Glen French returned as CEO, focusing on strategic realignment and operational efficiency.
Sales Strategy: Streamlined U.S. sales initiatives to focus on high-impact areas and better support treating physicians.
Sales Force Restructuring: Nearly all open U.S. sales positions filled, with a focus on reducing turnover and improving productivity.
Clinical Initiatives: Emphasis on the AeriSeal program and the CONVERT II trial to expand the addressable market by 20% globally.
Cost Management: Implemented a cost restructuring initiative reducing ongoing operating expenses by over 10%.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Expected to be between $90 million and $92 million, anticipating a return to growth in the U.S. and international markets in the second half of the year.
Operating Expenses for 2026: Projected to be between $113 million and $115 million, with a focus on maintaining investments in growth initiatives while reducing costs.
Cash Burn Reduction: Expected to decrease from $32 million in 2025 to $23 million in 2026.

4. Bad News, Challenges, or Points of Concern

U.S. Sales Decline: Experienced significant turnover in the sales organization and operational challenges, leading to weaker-than-expected revenue performance.
Market Dynamics: Increased competition and changes in hospital resource allocation could pose challenges.
China Market: Anticipated delays in sales due to pending registration certificate renewal, affecting revenue in the first half of 2026.
Sales Force Productivity: New hires may take 6 to 9 months to reach full productivity, delaying revenue recovery.

5. Notable Q&A Insights

Sales Force Turnover: Approximately 50% of the sales organization experienced turnover throughout 2025, impacting continuity.
Incentive Structure: Adjustments made to the sales incentive plan to better align with sales force motivation and performance.
Market Penetration: Positive long-term outlook despite short-term challenges, with macro trends favoring growth in the pulmonary sector.
LungTraX Detect Program: Not shelved but refocused on specific hospital systems where it can be most effective.

Overall, Pulmonx is taking decisive steps to address past challenges, streamline operations, and position itself for future growth, particularly through its clinical initiatives and improved sales strategies. However, the company faces significant hurdles in the short term, particularly in the U.S. market and with international sales dynamics.

LUNG — Pulmonx Corporation